Full-Time

Director – Treatment Center Strategy & Operations

T1D

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$184k - $276k/yr

+ Annual Bonus + Annual Equity Awards

Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid-Eligible: work remotely up to two days per week.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Specialty disease launch, transplant center, and/or novel treatment paradigm operational experience preferred
  • Demonstrated ability to take on complex operational problems with no obvious answer, and push forward innovative ideas to solve them
  • Analytical mindset, with demonstrated ability to develop strategy, make strategic recommendations, monitor performance, and allocate resources
  • Strong ability to execute plans, track and monitor them, and hold others accountable for them
  • Highly skilled in influencing cross-functional teams, including interfacing with key internal (HQ, manufacturing, distribution, global, field) and external stakeholders
  • Proven ability to be productive and successful in a fast-paced work environment, including managing multiple competing priorities with a high degree of autonomy
  • Able to successfully lead cross-functional teams, influencing without direct authority, with the interpersonal skills to foster collaboration and succeed in a highly matrixed environment
  • Demonstrated understanding of the legal, regulatory, and compliance requirements for pre- and post-approval activities and ability to model expected behavior for the team
  • Strong written communication skills, presentation delivery, and interpersonal skills to be effective in a team environment
  • Highly competent in a multitude of IT capabilities to support the business needs
Responsibilities
  • Serve as the primary point of contact for the US treatment center strategy, operations and readiness across all cross-functional teams; refine the treatment center approach, prioritization, and required operational readiness activities to ensure launch success
  • Develop and lead key processes, documents, training materials, and trackers to ensure a seamless operational experience for all potential treatment centers
  • Partner closely with Vertex field teams and external stakeholders to support all US center readiness steps and ongoing treatment journey operations; continuously learn and adapt plans to new insights
  • Lead the treatment center core team and coordination of activities for all treatment centers in the US; provide guidance to all support functions and continue to evolve the strategy as we learn more
  • Drive and implement the overall treatment center plan; partner with field leaders to shape treatment center account plans and objectives, and support them in execution
  • Manage the progression of critical activities, deliverables, resources, and timelines; ensure robust KPIs are established, monitored, and communicated to field and HQ teams
  • Represent the US commercial function for the global end-to-end process, and ensure any process changes are carefully considered by engaging a cross functional team to evaluate; partner to successfully execute mock operations and mock first patient exercises
Desired Qualifications
  • Specialty disease launch, transplant center, and/or novel treatment paradigm operational experience preferred
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's partnership with Orna could lead to breakthroughs in gene therapy for SCD and TDT.
  • Recent investments indicate strong investor confidence in Vertex's growth potential.
  • Vertex's non-opioid pain therapy research shows commitment to innovative pain management solutions.

What critics are saying

  • Vertex is under investigation for potential securities law violations, posing legal risks.
  • Mixed Phase II data for suzetrigine may delay its development and affect investor confidence.
  • Heavy reliance on partnerships exposes Vertex to risks if collaborations fail.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases like cystic fibrosis.
  • The company invests heavily in R&D and strategic biotech partnerships.
  • Vertex's innovative gene and cell therapies set it apart in the biotech industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Stat News
Mar 18th, 2025
Genetics expert is first NIH director to leave under Trump

He will be replaced on an interim basis by Director Ian Smith, a former Vertex Pharmaceuticals executive.

GlobeNewswire
Mar 18th, 2025
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into...

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

MarketBeat
Jan 17th, 2025
Channel Wealth LLC Invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Channel Wealth LLC invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Zenopa
Jan 8th, 2025
Vertex and Orna Partner for Innovative Gene Therapy Solutions

In a significant advancement for the biopharma industry, Vertex Pharmaceuticals has announced a partnership with Orna Therapeutics to develop cutting-edge in vivo gene editing therapies targeting sickle cell disease and beta thalassaemia.